FDA Regulatory Strategy & Designation Planning

RegulatoryRegulatory-affairs lead (ex-FDA reviewer caliber)

Given an asset's indication, seriousness, clinical evidence, endpoint type, modality, and prevalence, choose the optimal FDA expedited / special-designation strategy — which of Fast Track, Breakthrough Therapy, Accelerated Approval, Priority Review, RMAT, Orphan Drug, and Rare Pediatric Disease the asset qualifies for, and how to sequence them into one integrated pathway. The agent has read-only tools for the program rules, the scenario facts, per-program criteria, and real precedents, and must apply the criteria itself. Designations are not mutually exclusive.

Why this is fundable

Scarce expert who grades this: Regulatory-affairs lead / ex-FDA reviewer with expedited-program experience (~$300–500/hr loaded; former-reviewer consultants command more)
What one decision is worth: The right pathway can cut YEARS off approval and unlock first-to-market: Accelerated Approval on a surrogate can mean launching 2–4 years early, and a Rare Pediatric Disease voucher is independently sellable for ~$100M+. A wrong designation strategy (e.g. chasing AA with no valid surrogate, or missing RMAT/orphan) delays launch and forfeits exclusivity and incentives worth hundreds of millions.
Real-world data sources: FDA 'Expedited Programs for Serious Conditions — Drugs and Biologics' guidance; 21st Century Cures Act (RMAT); Orphan Drug Act; Rare Pediatric Disease PRV statute; Drugs@FDA and the FDA designation databases (Breakthrough, Orphan, RMAT). Curated teaching snapshot here; the criteria and precedents are refreshable against the live FDA guidance and designation lists.

Agent tools

list_programsget_program_criterialist_assetsget_assetfind_precedents

Expert grading rubric

Dimension	5 (excellent)	1 (poor)
Designation-eligibility accuracy	Correctly maps the scenario facts to EACH program's qualifying criteria — gets the QUALIFIES/DOESN'T call right for Fast Track, BTD, AA, Priority Review, RMAT, Orphan, and RPD, with the correct deciding criterion (e.g. regenerative modality for RMAT, prevalence for Orphan, pediatric for RPD).	Mis-assigns designations — e.g. claims RMAT for a small molecule, BTD on nonclinical-only data, or Orphan for a common disease.
Surrogate / endpoint reasoning	Applies Accelerated-Approval logic correctly: recognizes a surrogate/intermediate endpoint reasonably likely to predict benefit, distinguishes it from a mature clinical endpoint (mature OS = regular approval, not AA), and states the confirmatory-trial obligation.	Recommends Accelerated Approval off a mature OS readout, ignores the surrogate requirement, or omits the required confirmatory trial.
Unmet-need & seriousness framing	Frames seriousness of the condition and unmet need vs AVAILABLE therapy accurately, and uses that framing to justify (or rule out) each designation.	Asserts unmet need where effective approved therapy exists, or ignores seriousness/available-therapy when justifying designations.
Integrated pathway & agency-interaction strategy	Assembles a coherent, sequenced stack (designation → development support → approval pathway → review), exploits that designations are not mutually exclusive, prefers RMAT over BTD for regen products, and notes timing / FDA-meeting points.	Lists designations in isolation, double-counts redundant ones, or gives a flat list with no sequencing or agency-interaction logic.
Evidence faithfulness	Grounds every eligibility claim in the actual program criteria and the scenario facts returned by the tools; invents no designations, precedents, or facts.	Fabricates designations or precedents, invents prevalence/endpoint facts, or contradicts the criteria and scenario the tools returned.

Example queries

Recommend the FDA regulatory pathway and designation strategy for ASSET-01: a Phase 1/2 autologous DLL3 CAR-T in relapsed/refractory ES-SCLC showing a large ORR improvement (55% vs ~15-20% chemo) on a surrogate endpoint. Which expedited programs does it qualify for, and how should we sequence them?
We are the regulatory lead for ASSET-03, an AAV gene therapy for a rare, fatal, infantile-onset neurodegenerative disease (US prevalence ~1,200) with striking Phase 1/2 biomarker and motor-milestone data. Build the optimal FDA designation stack and explain the endpoint and confirmatory-evidence strategy.
Assess ASSET-02, an oral small molecule for lupus nephritis with only nonclinical and Phase 1 PK/safety data so far. Which FDA expedited designations can we credibly pursue now and which must wait, and why?
For ASSET-04, an anti-PD-1 mAb in 1L NSCLC with a completed Phase 3 showing a mature overall-survival benefit over an active comparator, what is the right FDA pathway? Specifically, is Accelerated Approval appropriate, and which designations actually apply?

Trajectories

model panel (compare side by side)

Model	Provider	Tier	Judge 1–5	Verdict
Claude Opus 4.8	anthropic	frontier	4.8	strong
GPT-4o mini	openai	small	3.8	—
Claude Haiku 4.5	anthropic	small	3.6	acceptable
GPT (frontier)	openai	frontier	3.2	flawed